The interdisciplinary team behind the most advanced BCI platform

OUR UNIQUE TEAM

Building neurotechnology that cannot be replicated

Paradromics team blends deep expertise in neurotechnology, engineering, data science, and proven go-to-market, Class III medical device experience.

Join our unique team

A male team member opening a machine while manufacturing the Paradromics Brain-Computer Interface Cortical Module

THE ROAD TO

Enabling neurotechnology

Founder and CEO Matt Angle, inspired by his research at Stanford, understood that a high-data rate, high-reliability brain-computer interface (BCI) could transform the scope and scale of brain-health applications.

2015

Research began on a high data-rate BCI platform in a lab at Stanford.

2016-2018

Secured NIH and DARPA contracts to explore core technology and establish proof of concept.

2019

Headquarters relocated to Austin, Texas to support long-term innovation and growth. The plentiful BBQ and beer was a plus.

2019-image

2019

Medical device veteran James Burrows joined Paradromics as COO, shaping our neurotechnology roots into a product focused company preparing for launch.

2020-2022

Pre-clinical demonstration of the highest channel count in vivo neural recording to date and the first chronic recordings from Connexus BCI.

2020-image

2023

Vikash Gilja, a tenured professor and early Neuralink employee, joined Paradromics as CSO, bringing strong expertise in machine learning and real-time neural decoding.

2023-image

2023

Established an office in Oakland, CA focused on machine learning and data science. Received FDA Breakthrough Device Designation for speech decoding, a critical milestone in regulatory advancement.

2024

Received second FDA Breakthrough Device Designation for control of digital devices. Accepted into the FDA Total Product Life Cycle Advisory Program (TAP).

2024

Started pre-clinical studies needed for Early Feasibility Study (EFS) FDA submission.

2025-image

March 2025

Announced Principal Investigator, Dr. David Brandman (UC Davis), and Investigator, Dr. Daniel Rubin (MGH/Harvard), for the upcoming Connexus BCI Clinical Study.

April 2025

Dr. Stephen Ryu, a neurosurgeon and key figure in the Stanford Neuroprosthetics Lab, joined Paradromics as CMO, guiding clinical decisions as we advance our first product.

June 2025

In conjunction with the University of Michigan, completed first-in-human recording using Connexus BCI, officially marking the transition to a clinical-stage company.